In the few cases in which antibody drug conjugates have already been used, the method has proven effective. In one instance, monoclonal ADCs were used in a clinical trial for patients with colorectal cancer. The specific antibody that was used, A7, was utilized as the drug carrier. The drugs mitomycin C (MMC) and neocarzinostatin (NCS) were covalently bound to A7, and the resulting ADCs were named A7-MMC and A7-NCS. In the end the conjugates were found to have a stronger effect on the cancer cells than plain MMC or NCS, and compared to the normal method of treatment which was less effective in that it spread evenly in all tissues, whereas the conjugates were concentrated mostly in the tumor cells (Kitamura K et al., 1988). Many involve the understanding and development of other types of antibodies (not ADCs, but simply antibodies) that have proven in many cases to be more effective than past methods of cancer treatment.
Recent comments